HRP20100272T2 - Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) - Google Patents

Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) Download PDF

Info

Publication number
HRP20100272T2
HRP20100272T2 HR20100272T HRP20100272T HRP20100272T2 HR P20100272 T2 HRP20100272 T2 HR P20100272T2 HR 20100272 T HR20100272 T HR 20100272T HR P20100272 T HRP20100272 T HR P20100272T HR P20100272 T2 HRP20100272 T2 HR P20100272T2
Authority
HR
Croatia
Prior art keywords
cr12ar12b
alkyl
hydrogen
amino
sulfonyl
Prior art date
Application number
HR20100272T
Other languages
English (en)
Inventor
Douglas Patterson Brian
Kim Sakata Sylvie
D. Nambu Mitchell
Bharat Kumar Patel Leena
Howard Tatlock John
Original Assignee
Pfizer Products Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated
Publication of HRP20100272T1 publication Critical patent/HRP20100272T1/hr
Publication of HRP20100272T2 publication Critical patent/HRP20100272T2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Spoj formule (I) naznačen time što: R1, R2, R3, R4 su nezavisno izabrani od vodika, C1-C6 alkil, -(CR12aR12b)thalo, -(CR12aR12b)tCN, -(CR12aR12b)tOR12a, -(CR12aR12b)tN(R12aR12b), -(CR12aR12b)tCF3, i -(CR12aR12b)tC6-C10 aril; R5 je vodik ili C1-C6 alkil; R6, R7, R8 i R9 su nezavisno izabrani od vodika, C1-C6alkil, -(CR12aR12b)thalo, -(CR12aR12b)tCN, -(CR12aR12b)tCF3,-(CR12aR12b)tOR12a, -(CR12aR12b)tN(R12aR12b), -(CR12aR12b)tR12a, -(CR12aR12b)tC3-C11cikloalkil; -(CR12aR12b)tC6-C10 aril, -(CR12aR12b)tC2-C10 heterociklil, -(CR12aR12b)theteroaril, -O(CR12aR12b)tR12a, -O(CR12aR12b)tC3-C11cikloalkil, -O(CR12aR12b)tC6-C10aril, -O(CR12aR12b)tC2-C10 heterociklil, -O(CR12aR12b)theteroaril, -O(CR12aR12b)tR12a i -O(CR12aR12b)tN(R12aR12b), gdje je svaka od spomenutih C1-C6alkil, C3-C11cikloalkil, C6-C10 aril i C2-C10 heterociklil, i heteroaril grupa po izboru supstituirana sa jednim ili više R14.R10 i R11 su nezavisno izabrani od vodika, -(CR12aR12b)tC1-C6 alkil, -(CR12aR12b)tC3-C11 cikloalkil, -(CR12aR12b)tC6-C10 aril, -(CR12aR12b)tC2-C10 heterociklil i -(CR12aR12b)theteroaril, gdje je svaka od spomenutih C1-C6 alkil, C3-C11 cikloalkil, C8-C10 aril, C2-C10 heterociklil, i heteroaril grupa po izboru supstituirana sa jednim ili više R13; iliR10 i R11 , zajedno sa atomom za koji su vezani, grade C2-C10 heterociklil grupu, po izboru supstituiranu sa jednim ili više R13;SVAKI R12A I R12B JE NEZAVISNO ODABRAN OD VODIKA I C1-C6 ALKIL; ILI R12A I R12B , ZAJEDNO SA ATOMOM ZA KOJI SU VEZANI, GRADE C3-C11 CIKLOALKIL ILI C2-C10 HETEROCIKLIL GRUPU; SVAKI OD R13 JE NEZAVISNO ODABRAN OD C1-C6 ALKIL, HALOGEN, -(CR12AR12B)TCN, -(CR12AR12B)TCF3, -(CR12AR12B)TOCF3, -(CR12AR12B)TC3-C11 CIKLOALKIL, -(CR12AR12B)TC6-C10 ARIL, -(CR12AR12B)TC2-C10 HETEROCIKLIL, -(CR12AR12B)THETEROARIL, -O(CR12AR12B)TR12A, -O(CR12AR12B)TC6-C10 ARIL, -O(CR12AR12B)TC2-C10 HETEROCIKLIL, -O(CR12AR12B)THETEROARIL, -(CR12AR12B)TCO2(C1-C6 ALKIL), -(CR12AR12B)TN(R12AR12B), -(CR12AR12B)TC(O)NR12AR12B, -(CR12AR12B)TOR12A, -(CR12AR12B)TS(O)R12A I -(CR12AR12B)TS(O)2R12A, GDJE JE SVAKA OD SPOMENUTIH C1-C6 ALKIL, C3-C11 CIKLOALKIL, C6-C10 ARIL, C2-C10 HETEROCIKLIL, I HETEROARIL GRUPA PO IZBORU SUPSTITUIRANA S JEDNIM ILI VIŠE R14;SVAKI OD R14 JE NEZAVISNO IZABRAN OD C1-C6 ALKIL, HALOGEN, -CN, -CF3, I OR12A; ISVAKI T JE NEZAVISNO IZABRAN OD 0, 1, 2, 3, 4, 5, I 6; ILINJEGOVA FARMACEUTSKI PRIHVATLJIVA SOL ILI SOLVAT. Patent sadrži još 18 patentnih zahtjeva.

Claims (19)

1. Spoj formule (I) [image] naznačen time što: R1, R2, R3, R4 su nezavisno izabrani od vodika, C1-C6 alkil, -(CR12aR12b)thalo, -(CR12aR12b)tCN, -(CR12aR12b)tOR12a, -(CR12aR12b)tN(R12aR12b), -(CR12aR12b)tCF3, i -(CR12aR12b)tC6-C10 aril; R5 je vodik ili C1-C6 alkil; R6, R7, R8 i R9 su nezavisno izabrani od vodika, C1-C6alkil, -(CR12aR12b)thalo, -(CR12aR12b)tCN, -(CR12aR12b)tCF3,-(CR12aR12b)tOR12a, -(CR12aR12b)tN(R12aR12b), -(CR12aR12b)tR12a, -(CR12aR12b)tC3-C11cikloalkil; -(CR12aR12b)tC6-C10 aril, -(CR12aR12b)tC2-C10 heterociklil, -(CR12aR12b)theteroaril, -O(CR12aR12b)tR12a, -O(CR12aR12b)tC3-C11cikloalkil, -O(CR12aR12b)tC6-C10aril, -O(CR12aR12b)tC2-C10 heterociklil, -O(CR12aR12b)theteroaril, -O(CR12aR12b)tR12a i -O(CR12aR12b)tN(R12aR12b), gdje je svaka od spomenutih C1-C6alkil, C3-C11cikloalkil, C6-C10 aril i C2-C10 heterociklil, i heteroaril grupa po izboru supstituirana sa jednim ili više R14. R10 i R11 su nezavisno izabrani od vodika, -(CR12aR12b)tC1-C6 alkil, -(CR12aR12b)tC3-C11 cikloalkil, -(CR12aR12b)tC6-C10 aril, -(CR12aR12b)tC2-C10 heterociklil i -(CR12aR12b)theteroaril, gdje je svaka od spomenutih C1-C6 alkil, C3-C11 cikloalkil, C8-C10 aril, C2-C10 heterociklil, i heteroaril grupa po izboru supstituirana sa jednim ili više R13; ili R10 i R11 , zajedno sa atomom za koji su vezani, grade C2-C10 heterociklil grupu, po izboru supstituiranu sa jednim ili više R13; svaki R12a i R12b je nezavisno odabran od vodika i C1-C6 alkil; ili R12a i R12b, zajedno sa atomom za koji su vezani, grade C3-C11 cikloalkil ili C2-C10 heterociklil grupu; svaki od R13 je nezavisno odabran od C1-C6 alkil, halogen, -(CR12aR12b)tCN, -(CR12aR12b)tCF3, -(CR12aR12b)tOCF3, -(CR12aR12b)tC3-C11 cikloalkil, -(CR12aR12b)tC6-C10 aril, -(CR12aR12b)tC2-C10 heterociklil, -(CR12aR12b)theteroaril, -O(CR12aR12b)tR12a, -O(CR12aR12b)tC6-C10 aril, -O(CR12aR12b)tC2-C10 heterociklil, -O(CR12aR12b)theteroaril, -(CR12aR12b)tCO2(C1-C6 alkil), -(CR12aR12b)tN(R12aR12b), -(CR12aR12b)tC(O)NR12aR12b, -(CR12aR12b)tOR12a, -(CR12aR12b)tS(O)R12a i -(CR12aR12b)tS(O)2R12a, gdje je svaka od spomenutih C1-C6 alkil, C3-C11 cikloalkil, C6-C10 aril, C2-C10 heterociklil, i heteroaril grupa po izboru supstituirana s jednim ili više R14; svaki od R14 je nezavisno izabran od C1-C6 alkil, halogen, -CN, -CF3, i OR12a; i svaki t je nezavisno izabran od 0, 1, 2, 3, 4, 5, i 6; ili njegova farmaceutski prihvatljiva sol ili solvat.
2. Spoj prema zahtjevu 1, naznačen time, što: R1, R2, R3, R4 su nezavisno izabrani od vodika, C1-C6 alkil, -(CR12aR12b)thalo, -(CR12aR12b)tCN, -(CR12aR12b)tOR12a, -(CR12aR12b)tN(R12aR12b), -(CR12aR12b)tCF3, i R10 i R11 su nezavisno izabrani od vodika, -(CR12aR12b)t C1-C6 alkil, -(CR12aR12b)t C3-C11 cikloalkil, -(CR12aR12b)t C6-C10 aril, -(CR12aR12b)t C2-C10 heterociklil i -(CR12aR12b)theteroaril, gdje je svaka od pomenutih C1-C6 alkil, C3-C11 cikloalkil, C6-C10 aril, C2-C10 heterociklil, i heteroaril grupa po izboru supstituirana sa jednim ili više R13; ili njegova farmaceutski prihvatljiva sol ili solvat.
3. Spoj prema zahtjevu 2, naznačen time, što: R1, R2, R3, R4 su nezavisno izabrani od vodika, C1-C6 alkil, halo, -CN, -OR12a, i -CF3; i R5 je vodik; ili njegova farmaceutski prihvatljiva sol ili solvat.
4. Spoj prema zahtjevu 3, naznačen time, što: R10 je vodik ili C1-C6 alkil; i R11 je izabran od -(CR12aR12b)t C1-C6 alkil, -(CR12aR12b)t C3-C11 cikloalkil, -(CR12aR12b)t C6-C10 aril, -(CR12aR12b)t C2-C10 heterociklil i -(CR12aR12b)theteroaril, gdje je svaka od spomenutih C1-C6 alkil, C3-C11 cikloalkil, C6-C10 aril, C2-C10 heterociklil, i heteroaril grupa po izboru supstituirana sa jednim ili više R13; ili njegova farmaceutski prihvatljiva sol ili solvat.
5. Spoj prema zahtjevu 4, naznačen time, što su R6, R7, R8 i R9 vodik, ili njegova farmaceutski prihvatljiva sol ili solvat.
6. Spoj prema zahtjevu 5, naznačen time, što: R11 je -(CH2)C6-C10 aril ili -(CH2)2C6-C10 aril, gdje je spomenuta C6-C10 aril grupa po izboru supstituirana sa jednim ili više R13; R12a je vodik ili C1-C6 alkil; i svaki od R13 je nezavisno izabran od vodika, C1-C6 alkil, halogen -CN, -CF3; i OCF3; ili njegova farmaceutski prihvatljiva sol ili solvat.
7. Spoj prema zahtjevu 6, naznačen time, što R1, R2 i R4 su vodik ̧ i R3 je C1-C6 alkil, -Cl, -F, -CN, -OCH3, -OCH2CH3, ili -CF3; R10 je vodik ili -CH3; i svaki od R13 je nezavisno izabran od, C1-C6 alkil, -Cl, -F, -CN, -CF3; i -OCF3; ili njegova farmaceutski prihvatljiva sol ili solvat.
8. spoj prema zahtjevu 1, naznačen time, što: R1, R2, i R4 su vodik, R3 je -CH3, -OCH3 ili -OCH3CH2 R5 je vodik; i R6, R7, R8 i R9 su vodik R10 je vodik ili -CH3, i R11 je –(CH2)C8-C10aril ili –(CH2)2C6-C10aril gdje je navedeni C6-C10 aril po izboru supstituiran jednim ili više R13; i svaki se R13neovisno bira od, C1-C6 alkil, -Cl, -F, -CN, -CF3; i -OCF3; ili njegova farmaceutski prihvatljiva sol ili solvat.
9. spoj prema zahtjevu 1, naznačen time, što: R1, R2, i R4 su vodik, R3 je -OCH3 ili -OCH3CH2 R5 je vodik; i R6, R7, R8 i R9 su vodik R10 je vodik ili -CH3, i R11 je –(CH2)C6-C10 aril ili –(CH2)2C6-C10 aril gdje je navedeni C6-C10 aril po izboru supstituiran jednim ili više supstituenata neovisno biranih od –Cl i –F; ili njegova farmaceutski prihvatljiva sol ili solvat.
10. spoj prema zahtjevu 1, naznačen time, što se odabire od: N-(3,4-difluorobenzil)-2-{[(5-metoksipiridin-3-il)amino]sulfonil}benzamid; N-[2-(2-metilfenil)etil]-2-{[(5-metilpiridin-3-il)amino]sulfonil}benzamid; N-(3,4-diklorobenzil)-2-{[(5-metilpiridin-3-il)amino]sulfonil}benzamid; N-[4-fluoro-3-(trifluorometil)benzil]-2-{[(5-metilpiridin-3-il)amino]sulfonil}benzamid; N-[4-fluoro-3-(trifluorometil)benzil]-2-{[(5-metoksipiridin-3 il)amino]sulfonil}benzamid; 2-{[(5-etoksipiridin-3-il)amino]sulfonil}-N-[2-(2-metilfenil)etil]benzamid; N-(3,4-diklorobenzil)-2-{[(5-etoksipiridin-3-il)amino]sulfonil}benzamid; N-(3,4-difluorobenzil)-2-{[(5-toksipiridin-3-il)amino]sulfonil}-N-metilbenzamid; 2-{[(4-etoksipiridin-3-il)amino]sulfonil}-N-[4-fluoro-3-(trifluorometil)benzil]benzamid; 2-{[(5-etoksipiridin-3-il)amino]sulfonil}-N-[4-fluoro-3-(trifluorometil)benzil]benzamid; N-(3,4-difluorobenzil)-2-{[(4-etoksipiridin-3-il)amino]sulfonil}-N-metilbenzamid; N-(4-kloro-2-metilbenzil)-2-{[(5-metoksipiridin-3-il)amino]sulfonil}benzamid; N-(3-kloro-2-metilbenzil)-2-{[(5-metoksipiridin-3-il)amino]sulfonil}benzamid; N-(3,5-diklorobenzil)-2-{[(5-metilpiridin-3-il)amino]sulfonil}benzamid; i N-(3,4-difluorobenzil)-2-{[(4-metoksipiridin-3-il)amino]sulfonil}-N-metilbenzamid; ili njegova farmaceutski prihvatljiva sol ili solvate.
11. spoj prema zahtjevu 1, naznačen time, što se odabire od: N-(3,4-difluorobenzil)-2-{[(4-metoksipiridin-3-il)amino]sulfonil}-Nmetilbenzamid; N-(3,4-difluorobenzil)-2-{[(4-metoksipiridin-3-il)amino]sulfonil}benzamid; N-[2-(2-fluorofenil)etil]-2-{[(5-metoksipiridin-3-il)amino]sulfonil}benzamid; N-[4-fluoro-3-(trifluorometil)benzil]-2-{[(4-metoksipiridin-3-il)amino]sulfonil}benzamid; N-(3,4-difluorobenzil)-2-{[(4-etoksipiridin-3-il)amino]sulfonil}benzamid; i N-(3,4-difluorobenzil)-2-{[(4-etoksipiridin-3-il)amino]sulfonil}-N-metilbenzamid; ili njegova farmaceutski prihvatljiva sol ili solvat.
12. farmaceutska kompozicija, naznačena time, što sadrži efektivnu količinu najmanje jednog spoja prema bilo kome od zahtjeva 1 do 11, i farmaceutski prihvatljiv nosač.
13. Farmaceutska kompozicija prema zahtjevu 12, naznačena time, što dalje sadrži inhibitor HIV proteaze odabranu od amprenavira, nelfinavira, ritonavira, sakvinavira, inviraze, lopinavira, atazanavira, palinavira, indinavira, tipranavira, darunavira, brecanavira, (4R)-N-alil-3-{(2S,3S)-2-hidroksi-3-[(3-hidroksi-2-metilbenzoil)amino]-4-fenilbutanoil}-5,5-dimetil-1,3-tiazolidlne-4-karboksamida, i fosamprenavir kalcija.
14. Primjena prvog spoja i drugog spoja za dobijanje lijeka za liječenje infekcije HIV-om kod sisavaca inficiranih HIV-om, naznačena time, što je prvi spoj odabran od onih prema bilo kojim od zahtjeva 1 do 11, a drugi spoj je anti-HIV spoj.
15. primjena prema zahtjevu 19, gdje je, naznačeni drugi spoj (N-{(1S)-3-[3-izopzopil-5-metil-4H-1,2,4-triazol-4-il]-egzo-8-azadiciklo[3.2.1]okt-8-il}-1-fenilpropil)-4,4-difluorocikloheksan-karboksamid), etil-1-endo-{8-[(3S)-3-(acetilamino)-3-(3-fluorofenil)propil]-8-azadiciklo[3.2.1]okt-3-il}-2-metil-4,5,6,7-tetrahidro-1H-imidazol[4,5-c]piridin-5-karboksilat, ili N-{(1S)-3-[3-endo-(5-izobutiril-2-metil-4,5,6,7-tetrahidro- 1H-imidazo[4.5-c]piridin-1-il)-8-azadiciklo[3.2.1]okt-8-il]-1-(3-fluorofenil)propil}-acetamid).
16. Primjena prema zahtjevu 14, gdje je naznačeni drugi spoj odabran od amprenavira, CGP-73547, CGP-61755, DMP-450, nelfinavira, ritonavira, sakvinavira, inviraze, lopinavira, TCM-126, atazanavira, palinavira, GS-333, KN I-413, KNI-272, LG-71350, CGP-61755, PD 173606, PD 173606, PD 177298, PD 178390, PD 178392, U-140690, ABT-378, DMP-450, AG-1776, MK-944, VX-478, indinavira, tipranavira, darunavira, brecanavira, DCP-681, DPC-684, (4R)-N-alil-3-{(2S,3S)-2-hidroksi-3-[(3-hidroksi-2-metilbenzoil)amino]-4-fenilbutanoil}-5,5-dimetil-1,3-tiazolidin-4-karboksamida, i fosamprenavir kalcija.
17. Primjena prvog spoja i drugog spoja, naznačena time što je za pripravu lijeka za poboljšanje farmakokinetike kod sisavca, gdje je navedeni prvi spoj anti-HIV spoj i navedeni drugi spoj se odabire od onih prema bilo kojem od zahtjeva 1 do 11.
18. Primjena prema zahtjevu 17, naznačena time što je navedeno anti-HIV spoj amprenavir, CGP-73547, CGP-61755, DMP-450, nelfinavir, ritonavir, sakvinavir, inviraza, lopinavir, TCM-126, atazanavir, palinavir, GS-333, KN I-413, KNI-272, LG-71350, CGP-61755, PD 173606, PD 173606, PD 177298, PD 178390, PD 178392, U-140690, ABT-378, DMP-450, AG-1776, MK-944, VX-478, indinavir, tipranavir, darunavir, brecanavir, DCP-681, DPC-684, (4R)-N-alil-3-{(2S,3S)-2-hidroksi-3-[(3-hidroksi-2-metilbenzoil)amino]-4-fenilbutanoil}-5,5-dimetil-1,3-tiazolidin-4-karboksamid, i fosamprenavir kalcij.
19. Spoj prema bilo kojem od zahtjeva 1 do 11, naznačen time da je za liječenje infekcije HIV-om kod sisavca inficiranog HIV-om.
HR20100272T 2005-09-23 2010-05-14 Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) HRP20100272T2 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US72015105P 2005-09-23 2005-09-23
US72311505P 2005-10-03 2005-10-03
US72546905P 2005-10-11 2005-10-11
US76225606P 2006-01-25 2006-01-25
US82166406P 2006-08-07 2006-08-07
PCT/IB2006/002639 WO2007034312A2 (en) 2005-09-23 2006-09-11 Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)

Publications (2)

Publication Number Publication Date
HRP20100272T1 HRP20100272T1 (hr) 2010-06-30
HRP20100272T2 true HRP20100272T2 (hr) 2010-07-31

Family

ID=37889174

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100272T HRP20100272T2 (hr) 2005-09-23 2010-05-14 Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)

Country Status (29)

Country Link
US (1) US7868026B2 (hr)
EP (1) EP1937639B1 (hr)
JP (1) JP4336738B2 (hr)
KR (1) KR100975448B1 (hr)
CN (1) CN101287708B (hr)
AT (1) ATE459603T1 (hr)
AU (1) AU2006293605B2 (hr)
BR (1) BRPI0616156A2 (hr)
CA (1) CA2621805C (hr)
CY (1) CY1110010T1 (hr)
DE (1) DE602006012713D1 (hr)
DK (1) DK1937639T3 (hr)
EA (1) EA014329B1 (hr)
EC (1) ECSP088296A (hr)
ES (1) ES2340200T3 (hr)
GE (1) GEP20115230B (hr)
HK (1) HK1120506A1 (hr)
HR (1) HRP20100272T2 (hr)
IL (1) IL189666A (hr)
MA (1) MA29791B1 (hr)
MY (1) MY143391A (hr)
NO (1) NO20081844L (hr)
NZ (1) NZ566136A (hr)
PL (1) PL1937639T3 (hr)
PT (1) PT1937639E (hr)
RS (2) RS20080118A (hr)
SI (1) SI1937639T1 (hr)
TN (1) TNSN08139A1 (hr)
WO (1) WO2007034312A2 (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000482A (es) * 2006-07-05 2009-01-27 Pfizer Prod Inc Compuestos terapeuticos.
AU2007343726A1 (en) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
ES2460897T3 (es) * 2007-10-04 2014-05-14 F. Hoffmann-La Roche Ag Derivados de ciclopropil aril amida y usos de los mismos
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
GEP20135992B (en) 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
CN102427810A (zh) * 2009-05-01 2012-04-25 拉夸里亚创药株式会社 作为trpm8拮抗剂的氨磺酰基苯甲酸衍生物
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2014000178A1 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
WO2016101118A1 (en) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Amidoethyl azole orexin receptor antagonists
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers

Also Published As

Publication number Publication date
NO20081844L (no) 2008-05-29
CA2621805A1 (en) 2007-03-29
SI1937639T1 (sl) 2010-07-30
CN101287708B (zh) 2012-02-29
MA29791B1 (fr) 2008-09-01
KR100975448B1 (ko) 2010-08-11
EP1937639B1 (en) 2010-03-03
ES2340200T3 (es) 2010-05-31
EP1937639A2 (en) 2008-07-02
CA2621805C (en) 2011-05-10
JP2009508931A (ja) 2009-03-05
IL189666A0 (en) 2008-08-07
IL189666A (en) 2011-12-29
ATE459603T1 (de) 2010-03-15
PL1937639T3 (pl) 2010-07-30
ECSP088296A (es) 2008-06-30
GEP20115230B (en) 2011-06-10
EA014329B1 (ru) 2010-10-29
JP4336738B2 (ja) 2009-09-30
WO2007034312A2 (en) 2007-03-29
TNSN08139A1 (fr) 2009-07-14
US20070167497A1 (en) 2007-07-19
KR20080038431A (ko) 2008-05-06
EA200800542A1 (ru) 2008-08-29
DE602006012713D1 (de) 2010-04-15
AU2006293605B2 (en) 2011-05-19
RS51349B (en) 2011-02-28
NZ566136A (en) 2010-04-30
HK1120506A1 (en) 2009-04-03
WO2007034312A3 (en) 2007-08-23
PT1937639E (pt) 2010-04-23
US7868026B2 (en) 2011-01-11
AU2006293605A1 (en) 2007-03-29
CN101287708A (zh) 2008-10-15
HRP20100272T1 (hr) 2010-06-30
CY1110010T1 (el) 2015-01-14
BRPI0616156A2 (pt) 2011-06-07
MY143391A (en) 2011-05-13
DK1937639T3 (da) 2010-05-10
RS20080118A (en) 2009-05-06

Similar Documents

Publication Publication Date Title
HRP20100272T2 (hr) Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)
AU2014223973B2 (en) Amide compounds for the treatment of HIV
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
CA3105748A1 (en) Pyridazine compounds for inhibiting nav1.8
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
DE602004021959D1 (de) Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
HRP20210783T1 (hr) Derivati karboksamida
BR0110240A (pt) Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
TW200932743A (en) Azole carboxamide compounds or salts thereof
AR065824A1 (es) Sulfonilbenzamidas sustituidas con heterociclos bloqueantes de los canales de sodio,formulaciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del dolor y particularmente del dolor cronico.
JP2013542247A (ja) Ｈｉｖ複製の阻害剤
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
CA2445333A1 (en) Quinoline derivatives and quinazoline derivatives having azolyl group
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
KR20230026404A (ko) Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
HRP20110938T1 (hr) Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora
AU2014234909A1 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
RU2017145922A (ru) МОДУЛЯТОРЫ ROR ГАММА(RORy)
AR111808A1 (es) Derivados de pirimidina como moduladores del receptor de pge2
HRP20230313T1 (hr) Modulatori receptora cxcr7 piperidina
SE9703377D0 (sv) New compounds
AR126073A1 (es) N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio